ABCELLERA BIOLOGICS
AbCellera focuses on therapeutic antibodies, screening, choosing, and analyzing millions of naturally produced antibodies to be used as next-generation drug candidates. It specializes in the fields of biotechnology, medicine, and therapeutics.
ABCELLERA BIOLOGICS
Industry:
Biotechnology Medical Therapeutics
Founded:
2012-01-01
Status:
Active
Contact:
(604) 559-9005
Total Funding:
371.22 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Nginx Amazon IPv6 Google Apps For Business Microsoft Azure DNS
Similar Organizations
Rakuten Medical
Rakuten Medical is a Bio-technology Company.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
Date | Company | Article | Price |
---|---|---|---|
2021-09-13 | Tetragenetics | Tetragenetics acquired by AbCellera Biologics | N/A |
2020-11-18 | Trianni | Trianni acquired by AbCellera Biologics | 90 M USD |
2020-08-20 | Dualogics - OrthoMab | Dualogics - OrthoMab acquired by AbCellera Biologics | N/A |
2018-08-01 | Lineage Biosciences | Lineage Biosciences acquired by AbCellera Biologics | N/A |
Investors List
Eli Lilly
Eli Lilly investment in Series B - AbCellera Biologics
Presight Capital
Presight Capital investment in Series B - AbCellera Biologics
Founders Fund
Founders Fund investment in Series B - AbCellera Biologics
OrbiMed
OrbiMed investment in Series B - AbCellera Biologics
DCVC
DCVC investment in Series B - AbCellera Biologics
Peter Thiel
Peter Thiel investment in Series B - AbCellera Biologics
Viking Global Investors
Viking Global Investors investment in Series B - AbCellera Biologics
University of Minnesota
University of Minnesota investment in Series B - AbCellera Biologics
Government of Canada
Government of Canada investment in Grant - AbCellera Biologics
Founders Fund
Founders Fund investment in Series A - AbCellera Biologics
Investments List
Date | Company | Article | Money raised |
---|---|---|---|
2020-09-30 | Invetx | AbCellera Biologics investment in Series A - Invetx | 10.25 M USD |
2020-02-24 | Invetx | AbCellera Biologics investment in Series A - Invetx | 15 M USD |
Key Employee Changes
Date | New article |
---|---|
2021-07-13 | AbCellera Appoints Neil Berkley as Chief Business Officer |
More informations about "AbCellera Biologics"
AbCellera - Wikipedia
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology firm that researches and develops human antibodies. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed a…See details»
Team - AbCellera
Carl is the founding CEO of AbCellera. As an entrepreneurial scientist working at the interface of engineering, biology, and computation, his work is represented in over 90 peer-reviewed …See details»
AbCellera Biologics Inc. - AbCellera Launches Second Phase of …
Sep 21, 2022 AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat …See details»
AbCellera Biologics Inc. - AbCellera Closes $105 Million Series B ...
May 27, 2020 AbCellera is a privately held biotech with a drug discovery platform that searches and analyzes natural immune systems to find antibodies that can be used to prevent and treat …See details»
AbCellera Biologics Inc. - AbCellera Continues …
Jun 22, 2021 AbCellera has also discovered a second antibody, LY-CoV1404, that is being advanced by Eli Lilly & Company to address emerging and future variants. This antibody has been shown to be effective against all currently …See details»
AbCellera - Overview, News & Similar companies | ZoomInfo.com
View AbCellera (www.abcellera.com) location in British Columbia, Canada , revenue, industry and description. ... Explore Complete Organization Structure. ... AbCellera Biologics (ABCL) Q2 …See details»
B.C.'s AbCellera Biologics expands research, production …
May 24, 2023 A Vancouver-based company that helped develop the first antibody therapy treatment for COVID-19 is expanding its research and development capacity as it continues to pursue world-leading new medicines, …See details»
AbCellera - LinkedIn
AbCellera discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders.See details»
Science - AbCellera
Developing potential first-in-class and best-in-class antibody medicines to create innovative, impactful medicines for patients around the world.See details»
Biotech company expands antibody research, production facilities …
May 24, 2023 AbCellera Biologics announced a new $700-million project on Wednesday that will add research and development capacity to a manufacturing plant that has been in the works …See details»
AbCellera Biologics Inc. - AbCellera Partners with the Governments …
May 24, 2023 About AbCellera Biologics Inc. AbCellera is breaking the barriers of conventional antibody drug discovery to bring better medicines to patients, sooner. AbCellera’s engine …See details»
AbCellera - Crunchbase Investor Profile & Investments
AbCellera is an antibody discovery and development company that develops antibody therapeutics to improve patient outcomes. AbCellera experienced a significant decline in its …See details»
Canada and British Columbia invest in AbCellera’s state-of-the-art ...
May 24, 2023 AbCellera is a Canadian technology company that is breaking the barriers of conventional antibody drug discovery to bring better medicines to patients, sooner.See details»
Partners - AbCellera
Our engine integrates expert teams, technology, and facilities with the data science and automation needed to advance antibody-based medicines from target to clinic with greater …See details»
AbCellera to Build Antibody Manufacturing Facility in Canada
Jun 23, 2021 AbCellera has unveiled plans for the construction of a Good Manufacturing Practices (GMP) manufacturing facility in Vancouver for the production of therapeutic …See details»
AbCellera Biologics Inc. - Investor Relations
Nov 4, 2024 AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, …See details»
Walleye Capital LLC Purchases Shares of 256,881 AbCellera …
3 days ago AbCellera Biologics had a negative net margin of 533.32% and a negative return on equity of 15.73%. During the same period last year, the firm earned ($0.10) earnings per …See details»
AbCellera Biologics Inc. - AbCellera to Collaborate with Biogen to ...
Mar 11, 2024 AbCellera’s engine integrates expert teams, technology, and facilities with the data science and automation needed to propel antibody-based medicines from target to clinic in …See details»
AbCellera Biologics (ABCL) Earnings Date and Reports 2025
2 days ago AbCellera Biologics announced Q3 2024 earnings on November 4, 2024, reporting an EPS of -$0.17, which missed analysts' consensus estimates of -$0.14 by $0.03. Quarterly …See details»
AbCellera Biologics Inc. - AbCellera Receives $175.6 million from …
May 3, 2020 AbCellera is a privately held Canadian biotech with a drug discovery platform that searches and analyzes natural immune systems to find antibodies that can be used to prevent …See details»